Two-Drug immune attack shows promise against tough cancers
NCT ID NCT03625323
First seen Apr 25, 2026 · Last updated May 23, 2026 · Updated 5 times
Summary
This study tested a combination of two immunotherapy drugs (eftilagimod alpha and pembrolizumab) in 187 adults with advanced non-small cell lung cancer or head and neck cancer that had not responded to prior treatment. The goal was to see if the combo could shrink tumors safely. Results measured tumor response rates using standard criteria.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Oncology Consultants
Huston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.